Molecular structure of Rasagiline, CAS Number: 136236-51-6
Rasagiline (CAS 136236-51-6)
Alternate Names:
(R)-N-2-Propynyl-1-indanamine
Application:
Rasagiline is an irreversible inhibitor of monoamine oxidase
CAS Number:
136236-51-6
Molecular Weight:
171.24
Molecular Formula:
C12H13N
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Rasagiline is a selective irreversible inhibitor of MAO-B (monoamine oxidase-B). Rasagiline is demonstrated to increase survival of rat E14 mesencephalic dopaminergic neurons in vitro and to increase total neuronal (MAP2-positive) survival. Rasagiline has also demonstrated to increase the percentage of tyrosine hydroxylase positive cells and the number of neurons per field in a rat fetal mesencephalic cell culture.
Rasagiline (CAS 136236-51-6) References
- Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. | Youdim, MB., et al. J Neurosci Res. 79: 172-9. PMID: 15573406
- Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. | Chen, JJ. and Ly, AV. 2006. Am J Health Syst Pharm. 63: 915-28. PMID: 16675649
- Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? | Ahlskog, JE. and Uitti, RJ. 2010. Neurology. 74: 1143-8. PMID: 20368634
- The role of rasagiline in the treatment of Parkinson's disease. | Leegwater-Kim, J. and Bortan, E. 2010. Clin Interv Aging. 5: 149-56. PMID: 20517484
- Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. | Weinreb, O., et al. 2010. Prog Neurobiol. 92: 330-44. PMID: 20600573
- Efficacy of rasagiline for the treatment of Parkinson's disease: an updated meta-analysis. | Chang, Y., et al. 2017. Ann Med. 49: 421-434. PMID: 28293967
- Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease. | Naoi, M., et al. 2020. J Neural Transm (Vienna). 127: 131-147. PMID: 31993732
- Pharmacology and neuroprotective properties of rasagiline. | Finberg, JP., et al. 1996. J Neural Transm Suppl. 48: 95-101. PMID: 8988465
- Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. | Finberg, JP., et al. 1998. Neuroreport. 9: 703-7. PMID: 9559942
- (R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. | Sterling, J., et al. 1998. J Neural Transm Suppl. 52: 301-5. PMID: 9564630
Inhibitor of:
EG226604, G3BP1, Giantin, MAO-A, MAO-B, Monoamine Oxidase, NCDN, NDUFA (NADH:ubiquinone oxidoreductase subunit), NDUFB (NADH:ubiquinone oxidoreductase subunit), Rho D, SAPAP1, and Sorting Nexin (SNX).Activator of:
βPIX, D5DR, FEV, STOP, and synphilin-1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Rasagiline, 25 mg | sc-204875 | 25 mg | $101.00 | |||
Rasagiline, 100 mg | sc-204875A | 100 mg | $210.00 |